Clinically, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers are mainstay treatments for hypertension and heart failure (HF). Following myocardial infarction (MI), RAAS inhibition stabilizes adverse cardiac remodeling and function and limits progression to HF. Here, ACE is linked to myocardial infarction.